Letter to the Editor: Commentary on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients"

被引：1
|
作者：
Tae, Bum Sik [1 ]
Choi, Hoon [1 ]
Bae, Jae Hyun [1 ]
机构：
[1] Korea Univ Coll Med, Korea Univ Ansan Hosp, Dept Urol, 123 Jeokgeum Ro, Ansan 15355, South Korea
来源：
INTERNATIONAL NEUROUROLOGY JOURNAL | 2017年 / 21卷 / 03期
关键词：
D O I：
10.5213/inj.1734962.481
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：229 / 230
页数：2
相关论文
共 39 条
  • [1] Evidence Is Enough?: A Systematic Review and Network MetaAnalysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients
    Kim, Su Jin
    Shin, In-Soo
    Eun, Sung-Jong
    Whangbo, Taeg-Keun
    Kim, Jin Wook
    Cho, Young Sam
    Kim, Joon Chul
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2017, 21 (01) : 29 - 37
  • [2] The Authors Reply: Reply on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients"
    Kim, Su Jin
    Shin, In-Soo
    Eun, Sung-Jong
    Whangbo, Taeg-Keun
    Kim, Jin Wook
    Cho, Young Sam
    Kim, Joon Chul
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2017, 21 (03) : 231 - 232
  • [3] Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia
    Chung, Jae-Wook
    Choi, Seock Hwan
    Kim, Bum Soo
    Kim, Tae-Hwan
    Yoo, Eun Sang
    Kim, Chun Il
    Lee, Kyung Seop
    Kwon, Tae Gyun
    KOREAN JOURNAL OF UROLOGY, 2011, 52 (07) : 479 - 484
  • [4] THE EFFECT IN SWITCHING PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA FROM TAMSULOSIN 0.2 MG TO 0.4 MG
    Supadach, T.
    Sompol, P.
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 : 74 - 74
  • [5] Efficacy and tolerability of tamsulosin 0.4 mg in Asian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg: A randomized placebo controlled trial
    Kim, Jung Jun
    Han, Deok Hyun
    Sung, Hyun Hwan
    Choo, Seol Ho
    Lee, Sung Won
    INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (07) : 677 - 682
  • [6] EVIDENCE OF TAMSULOSIN 0.4 MG AS INITIAL DOSE IN ASIAN BPH PATIENTS: CONSIDERATION THROUGH NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Kim, Su Jin
    Kim, Khae Hawn
    Cho, Sung Tae
    Kim, Hyeong Gon
    Yoon, Hana
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 : S56 - S57
  • [7] Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis
    Cai, Tong
    Cui, Yuanshan
    Yu, Shaoxia
    Li, Qian
    Zhou, Zhongbao
    Gao, Zhenli
    AMERICAN JOURNAL OF MENS HEALTH, 2020, 14 (02)
  • [8] General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis
    Shim, Sung Ryul
    Kim, Jae Heon
    Choi, Hoon
    Lee, Won Jin
    Kim, Hae Joon
    Bae, Min Young
    Hwang, Sung Dong
    Kim, Khae Hwan
    Bae, Jae Hyun
    Yoon, Sang Jin
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (02) : 353 - 365
  • [9] The efficacy of mirabegron 50 mg additional therapy on tamsulosin 0.2 mg/0.4 mg and dutasteride 0.5 mg combination therapy for lower urinary tract symptoms of elderly treatment-naive benign prostatic hyperplasia patients: prospective analysis
    Chung, H. S.
    Lee, H. -Y.
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 : 20 - 20
  • [10] Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction
    Ahn, Sun Tae
    Lee, Dong Hyun
    Jeong, Hyeong Guk
    Kim, Jong Wook
    Oh, Mi Mi
    Park, Hong Seok
    Moon, Du Geon
    INVESTIGATIVE AND CLINICAL UROLOGY, 2020, 61 (01) : 81 - 87
1234